Novo Nordisk Utilizes Gefion AI Supercomputer for Drug Discovery

Novo Nordisk has partnered with DCAI to leverage the Gefion AI supercomputer for advancing drug discovery and healthcare innovation, as announced in a press release.

Novo Nordisk has entered into a multiyear agreement with DCAI to utilize the Gefion AI supercomputer, as announced in a press release. This collaboration aims to enhance drug discovery and healthcare innovation by harnessing Gefion's advanced computational capabilities.

The agreement allows Novo Nordisk to access Gefion's NVIDIA DGX SuperPod technology, which is expected to accelerate the development of new therapies by processing vast datasets. This initiative is part of Novo Nordisk's strategic focus on integrating AI across its value chain.

Gefion, ranked 21st on the Top500 list of supercomputers, will support Novo Nordisk in tackling compute-heavy challenges such as AI-based protein engineering and biological modeling. The partnership also includes collaboration with NVIDIA to develop customized models for early research and discovery.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish like Life AI Weekly.

Also, consider following us on social media:

Healthcare & Life Sciences AI

AI Brief (X)

More from: Healthcare & Life Sciences

Lunit AI Supports Mass Screening During 2025 Hajj in Saudi Arabia

Jun 16

Genesis Therapeutics Appoints Aleksandra Faust as Chief AI Officer

Jun 13

Ellipsis Health Unveils AI Care Manager Sage with $45M Funding

Jun 13

Deep Apple and Novo Nordisk Partner on Cardiometabolic Drug Discovery

Jun 13

Outcomes4Me Acquires Mika Health App to Enhance AI-Driven Cancer Care

Jun 13

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.